Saurabh P. Dahiya

Hematology

965 High St
Palo Alto, CA 94301

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 119 publications

Up and coming early phase CAR T-cell Therapy for treating relapsed or refractory large B-cell lymphoma.

Up and coming early phase CAR T-cell Therapy for treating relapsed or refractory large B-cell lymphoma.

Journal: Expert opinion on investigational drugs

Published: August 31, 2026

Multi-antigen chimeric antigen receptor-T cell therapy for relapsed/refractory B cell lymphomas.

Multi-antigen chimeric antigen receptor-T cell therapy for relapsed/refractory B cell lymphomas.

Journal: Frontiers in immunology

Published: June 04, 2026

Durable efficacy and manageable long-term safety of lisocabtagene maraleucel in 3L+ FL: 3-year update from TRANSCEND FL.

Durable efficacy and manageable long-term safety of lisocabtagene maraleucel in 3L+ FL: 3-year update from TRANSCEND FL.

Journal: Blood

Published: April 01, 2026

Post CAR-T Measurable Residual Disease Monitoring in Mantle Cell Lymphoma Enables Early Detection of Disease Relapse.

Post CAR-T Measurable Residual Disease Monitoring in Mantle Cell Lymphoma Enables Early Detection of Disease Relapse.

Journal: American journal of hematology

Published: January 08, 2026

Treatment kinetics and local response during and after bridging radiotherapy prior to CAR-T cell therapy for lymphomas.

Treatment kinetics and local response during and after bridging radiotherapy prior to CAR-T cell therapy for lymphomas.

Journal: Leukemia & lymphoma

Published: December 26, 2025

Rapid Peak Cilta-cel Expansion is Associated with Delayed Neurotoxicity in Multiple Myeloma.

Rapid Peak Cilta-cel Expansion is Associated with Delayed Neurotoxicity in Multiple Myeloma.

Journal: Blood

Published: December 15, 2025

Mapping the immune orchestra of zamtocabtagene autoleucel in primary CNS lymphoma.

Mapping the immune orchestra of zamtocabtagene autoleucel in primary CNS lymphoma.

Journal: Haematologica

Published: December 03, 2025

CAR19 therapy drives expansion of clonal hematopoiesis and associated cytopenias.

CAR19 therapy drives expansion of clonal hematopoiesis and associated cytopenias.

Journal: Research square

Published: November 24, 2025

Superior Chronic Graft-versus-Host Disease-Free Survival with Post-Transplant Cyclophosphamide Relative to Tacrolimus/Methotrexate in Myeloablative HLA-Matched Allogeneic Hematopoietic Cell Transplantation.

Superior Chronic Graft-versus-Host Disease-Free Survival with Post-Transplant Cyclophosphamide Relative to Tacrolimus/Methotrexate in Myeloablative HLA-Matched Allogeneic Hematopoietic Cell Transplantation.

Journal: Transplantation and cellular therapy

Published: November 18, 2025

Early steroid and anakinra use to manage axicabtagene ciloleucel toxicity reduces the total duration of CRS and ICANS.

Early steroid and anakinra use to manage axicabtagene ciloleucel toxicity reduces the total duration of CRS and ICANS.

Journal: Blood advances

Published: November 13, 2025

Early Steroid and Anakinra Use to Manage Axicabtagene Ciloleucel Toxicity Reduces the Total Duration of CRS and ICANS.

Early Steroid and Anakinra Use to Manage Axicabtagene Ciloleucel Toxicity Reduces the Total Duration of CRS and ICANS.

Journal: Blood advances

Published: November 13, 2025

Real-World Experience With a ZUMA-1 Cohort 4 Adopted Approach to CRS and ICANS in CAR-T Recipients.

Real-World Experience With a ZUMA-1 Cohort 4 Adopted Approach to CRS and ICANS in CAR-T Recipients.

Journal: European journal of haematology

Published: October 20, 2025

Showing 1-12 of 119

Last Updated: 09/26/2026